Neuromodulation Market By Technology (Internal Neuromodulation, External Neuromodulation), By Application (Chronic Pain, Urinary And Fecal Incontinence, Migraine, Failed Back Syndrome, Parkinson Disease, Epilepsy, Tremor, Depression, Other Applications), By Biomaterial (Metallic Biomaterials, Polymeric Biomaterials, Ceramic Biomaterials), : Global Opportunity Analysis and Industry Forecast, 2020-2030
The global neuromodulation market was valued at $2,480.2 million in 2020, and is projected to reach $4,342.5 million by 2030, registering a CAGR of 6.2% from 2021 to 2030. Epilepsy, Alzheimer disease, cerebrovascular diseases, and Parkinson's disease are the most common neurological disorder, which affect the central and peripheral nervous system. These neurological disorders are caused by genetic disorders, congenital abnormalities or disorders, infections, lifestyle or environmental health problems, including malnutrition, and brain injury, spinal cord injury or nerve injury. Bacterial, viral, and fungal infections also responsible for neurological disorders.
The increase in prevalence of neurological diseases globally drives the growth of the neuromodulation market. For instance, according to the Epilepsy Action organization, which is the British charity providing information for population with epilepsy, in February 2022, around 600,000 population are diagnosed with epilepsy, in UK, which is around one in every 100 population. In addition, increase in geriatric population propels the growth of neuromodulation market. The increase in R&D activities in the pharmaceutical sector and rise in number of clinical trials in the neuromodulation devices by manufacturers and researchers also contribute in the growth of market. Furthermore, surge in awareness for use of neuromodulation devices further boosts the market growth. The rise in number of hospitals and well-developed healthcare infrastructure further contributes in market growth.
In addition, increase in advancement in technology for neuromodulation devices and rise in product launch in the field of neuromodulation devices contribute in the growth of the neuromodulation market. However, the high cost of neuromodulation devices are expected to limit the growth of market.
The neuromodulation market is segmented on the basis of technology, application, biomaterial, and region. By technology, the market is mainly categorized into internal neuromodulation and external neuromodulation. By application, it is categorized in chronic pain, urinary and fecal incontinence, migraine, failed back syndrome, Parkinson disease, epilepsy, tremor, depression, and other applications. On the basis of biomaterial, it is divided into, metallic biomaterials, polymeric biomaterials, and ceramic biomaterials. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Abbott, Aleva, Neurotherapeutics SA., Boston Scientific Corporation, LivaNova, Medtronic, MicroTransponder, Neuronetics, NeuroPace Inc., NeuroSigma, and Nevro Corporation.
KEY BENEFITS FOR STAKEHOLDERS
The report provides an in-depth analysis of the global neuromodulation market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global neuromodulation market growth.
Key Market Segments
By Technology
Internal Neuromodulation
External Neuromodulation
By Application
Chronic Pain
Urinary And Fecal Incontinence
Migraine
Failed Back Syndrome
Parkinson Disease
Epilepsy
Tremor
Depression
Other Applications
By Biomaterial
Metallic Biomaterials
Polymeric Biomaterials
Ceramic Biomaterials
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
LivaNova PLC
Nevro Corporation
Medtronic
NeuroSigma
Neuronetics
Bioventus Inc.
NeuroPace Inc
MicroTransponder
MicroTransponder
Boston Scientific Corporation
Abbott
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: NEUROMODULATION MARKET, BY TECHNOLOGY
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Internal Neuromodulation
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 External Neuromodulation
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- CHAPTER 5: NEUROMODULATION MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Chronic Pain
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Urinary And Fecal Incontinence
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Migraine
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Failed Back Syndrome
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Parkinson Disease
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
- 5.7 Epilepsy
- 5.7.1 Key market trends, growth factors and opportunities
- 5.7.2 Market size and forecast, by region
- 5.7.3 Market analysis by country
- 5.8 Tremor
- 5.8.1 Key market trends, growth factors and opportunities
- 5.8.2 Market size and forecast, by region
- 5.8.3 Market analysis by country
- 5.9 Depression
- 5.9.1 Key market trends, growth factors and opportunities
- 5.9.2 Market size and forecast, by region
- 5.9.3 Market analysis by country
- 6.0 Other Applications
- 6.0.1 Key market trends, growth factors and opportunities
- 6.0.2 Market size and forecast, by region
- 6.0.3 Market analysis by country
- CHAPTER 6: NEUROMODULATION MARKET, BY BIOMATERIAL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Metallic Biomaterials
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Polymeric Biomaterials
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Ceramic Biomaterials
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: NEUROMODULATION MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Technology
- 7.2.3 North America Market size and forecast, by Application
- 7.2.4 North America Market size and forecast, by Biomaterial
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Technology
- 7.2.5.1.2 Market size and forecast, by Application
- 7.2.5.1.3 Market size and forecast, by Biomaterial
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Technology
- 7.2.5.2.2 Market size and forecast, by Application
- 7.2.5.2.3 Market size and forecast, by Biomaterial
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Technology
- 7.2.5.3.2 Market size and forecast, by Application
- 7.2.5.3.3 Market size and forecast, by Biomaterial
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Technology
- 7.3.3 Europe Market size and forecast, by Application
- 7.3.4 Europe Market size and forecast, by Biomaterial
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Technology
- 7.3.5.1.2 Market size and forecast, by Application
- 7.3.5.1.3 Market size and forecast, by Biomaterial
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Technology
- 7.3.5.2.2 Market size and forecast, by Application
- 7.3.5.2.3 Market size and forecast, by Biomaterial
- 7.3.5.3 United Kingdom
- 7.3.5.3.1 Market size and forecast, by Technology
- 7.3.5.3.2 Market size and forecast, by Application
- 7.3.5.3.3 Market size and forecast, by Biomaterial
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Technology
- 7.3.5.4.2 Market size and forecast, by Application
- 7.3.5.4.3 Market size and forecast, by Biomaterial
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Technology
- 7.3.5.5.2 Market size and forecast, by Application
- 7.3.5.5.3 Market size and forecast, by Biomaterial
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Technology
- 7.3.5.6.2 Market size and forecast, by Application
- 7.3.5.6.3 Market size and forecast, by Biomaterial
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Technology
- 7.4.3 Asia-Pacific Market size and forecast, by Application
- 7.4.4 Asia-Pacific Market size and forecast, by Biomaterial
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Technology
- 7.4.5.1.2 Market size and forecast, by Application
- 7.4.5.1.3 Market size and forecast, by Biomaterial
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Technology
- 7.4.5.2.2 Market size and forecast, by Application
- 7.4.5.2.3 Market size and forecast, by Biomaterial
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Technology
- 7.4.5.3.2 Market size and forecast, by Application
- 7.4.5.3.3 Market size and forecast, by Biomaterial
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Technology
- 7.4.5.4.2 Market size and forecast, by Application
- 7.4.5.4.3 Market size and forecast, by Biomaterial
- 7.4.5.5 Rest of Asia-Pacific
- 7.4.5.5.1 Market size and forecast, by Technology
- 7.4.5.5.2 Market size and forecast, by Application
- 7.4.5.5.3 Market size and forecast, by Biomaterial
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Technology
- 7.5.3 LAMEA Market size and forecast, by Application
- 7.5.4 LAMEA Market size and forecast, by Biomaterial
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Technology
- 7.5.5.1.2 Market size and forecast, by Application
- 7.5.5.1.3 Market size and forecast, by Biomaterial
- 7.5.5.2 Turkey
- 7.5.5.2.1 Market size and forecast, by Technology
- 7.5.5.2.2 Market size and forecast, by Application
- 7.5.5.2.3 Market size and forecast, by Biomaterial
- 7.5.5.3 Saudi Arabia
- 7.5.5.3.1 Market size and forecast, by Technology
- 7.5.5.3.2 Market size and forecast, by Application
- 7.5.5.3.3 Market size and forecast, by Biomaterial
- 7.5.5.4 South Africa
- 7.5.5.4.1 Market size and forecast, by Technology
- 7.5.5.4.2 Market size and forecast, by Application
- 7.5.5.4.3 Market size and forecast, by Biomaterial
- 7.5.5.5 Rest of LAMEA
- 7.5.5.5.1 Market size and forecast, by Technology
- 7.5.5.5.2 Market size and forecast, by Application
- 7.5.5.5.3 Market size and forecast, by Biomaterial
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 LivaNova PLC
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Nevro Corporation
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Medtronic
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 NeuroSigma
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Neuronetics
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Bioventus Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 NeuroPace Inc
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 MicroTransponder
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 MicroTransponder
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Boston Scientific Corporation
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Abbott
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
- TABLE 2. NEUROMODULATION MARKET REVENUE, FOR INTERNAL NEUROMODULATION, BY REGION , 2020-2030,($MILLION)
- TABLE 3. NEUROMODULATION MARKET INTERNAL NEUROMODULATION BY COUNTRY, 2020-2030,($MILLION)
- TABLE 4. NEUROMODULATION MARKET REVENUE, FOR EXTERNAL NEUROMODULATION, BY REGION , 2020-2030,($MILLION)
- TABLE 5. NEUROMODULATION MARKET EXTERNAL NEUROMODULATION BY COUNTRY, 2020-2030,($MILLION)
- TABLE 6. GLOBAL NEUROMODULATION MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 7. NEUROMODULATION MARKET REVENUE, FOR CHRONIC PAIN, BY REGION , 2020-2030,($MILLION)
- TABLE 8. NEUROMODULATION MARKET CHRONIC PAIN BY COUNTRY, 2020-2030,($MILLION)
- TABLE 9. NEUROMODULATION MARKET REVENUE, FOR URINARY AND FECAL INCONTINENCE, BY REGION , 2020-2030,($MILLION)
- TABLE 10. NEUROMODULATION MARKET URINARY AND FECAL INCONTINENCE BY COUNTRY, 2020-2030,($MILLION)
- TABLE 11. NEUROMODULATION MARKET REVENUE, FOR MIGRAINE, BY REGION , 2020-2030,($MILLION)
- TABLE 12. NEUROMODULATION MARKET MIGRAINE BY COUNTRY, 2020-2030,($MILLION)
- TABLE 13. NEUROMODULATION MARKET REVENUE, FOR FAILED BACK SYNDROME, BY REGION , 2020-2030,($MILLION)
- TABLE 14. NEUROMODULATION MARKET FAILED BACK SYNDROME BY COUNTRY, 2020-2030,($MILLION)
- TABLE 15. NEUROMODULATION MARKET REVENUE, FOR PARKINSON DISEASE, BY REGION , 2020-2030,($MILLION)
- TABLE 16. NEUROMODULATION MARKET PARKINSON DISEASE BY COUNTRY, 2020-2030,($MILLION)
- TABLE 17. NEUROMODULATION MARKET REVENUE, FOR EPILEPSY, BY REGION , 2020-2030,($MILLION)
- TABLE 18. NEUROMODULATION MARKET EPILEPSY BY COUNTRY, 2020-2030,($MILLION)
- TABLE 19. NEUROMODULATION MARKET REVENUE, FOR TREMOR, BY REGION , 2020-2030,($MILLION)
- TABLE 20. NEUROMODULATION MARKET TREMOR BY COUNTRY, 2020-2030,($MILLION)
- TABLE 21. NEUROMODULATION MARKET REVENUE, FOR DEPRESSION, BY REGION , 2020-2030,($MILLION)
- TABLE 22. NEUROMODULATION MARKET DEPRESSION BY COUNTRY, 2020-2030,($MILLION)
- TABLE 23. NEUROMODULATION MARKET REVENUE, FOR OTHER APPLICATIONS, BY REGION , 2020-2030,($MILLION)
- TABLE 24. NEUROMODULATION MARKET OTHER APPLICATIONS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 25. GLOBAL NEUROMODULATION MARKET, BY BIOMATERIAL, 2020-2030,($MILLION)
- TABLE 26. NEUROMODULATION MARKET REVENUE, FOR METALLIC BIOMATERIALS, BY REGION , 2020-2030,($MILLION)
- TABLE 27. NEUROMODULATION MARKET METALLIC BIOMATERIALS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 28. NEUROMODULATION MARKET REVENUE, FOR POLYMERIC BIOMATERIALS, BY REGION , 2020-2030,($MILLION)
- TABLE 29. NEUROMODULATION MARKET POLYMERIC BIOMATERIALS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 30. NEUROMODULATION MARKET REVENUE, FOR CERAMIC BIOMATERIALS, BY REGION , 2020-2030,($MILLION)
- TABLE 31. NEUROMODULATION MARKET CERAMIC BIOMATERIALS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 32. NEUROMODULATION MARKET, BY REGION, 2020-2030,($MILLION)
- TABLE 33. NORTH AMERICA NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
- TABLE 34. NORTH AMERICA NEUROMODULATION MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 35. NORTH AMERICA NEUROMODULATION MARKET, BY BIOMATERIAL, 2020-2030,($MILLION)
- TABLE 36. NORTH AMERICA NEUROMODULATION MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 37. U.S. NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 38. U.S. NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 39. U.S. NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 40. CANADA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 41. CANADA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 42. CANADA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 43. MEXICO NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 44. MEXICO NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 45. MEXICO NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 46. EUROPE NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
- TABLE 47. EUROPE NEUROMODULATION MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 48. EUROPE NEUROMODULATION MARKET, BY BIOMATERIAL, 2020-2030,($MILLION)
- TABLE 49. EUROPE NEUROMODULATION MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 50. GERMANY NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 51. GERMANY NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 52. GERMANY NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 53. FRANCE NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 54. FRANCE NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 55. FRANCE NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 56. UNITED KINGDOM NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 57. UNITED KINGDOM NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 58. UNITED KINGDOM NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 59. ITALY NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 60. ITALY NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 61. ITALY NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 62. SPAIN NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 63. SPAIN NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 64. SPAIN NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 65. REST OF EUROPE NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 66. REST OF EUROPE NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 67. REST OF EUROPE NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 68. ASIA-PACIFIC NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
- TABLE 69. ASIA-PACIFIC NEUROMODULATION MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 70. ASIA-PACIFIC NEUROMODULATION MARKET, BY BIOMATERIAL, 2020-2030,($MILLION)
- TABLE 71. ASIA-PACIFIC NEUROMODULATION MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 72. CHINA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 73. CHINA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 74. CHINA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 75. JAPAN NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 76. JAPAN NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 77. JAPAN NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 78. INDIA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 79. INDIA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 80. INDIA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 81. AUSTRALIA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 82. AUSTRALIA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 83. AUSTRALIA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 84. REST OF ASIA-PACIFIC NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 86. REST OF ASIA-PACIFIC NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 87. LAMEA NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
- TABLE 88. LAMEA NEUROMODULATION MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 89. LAMEA NEUROMODULATION MARKET, BY BIOMATERIAL, 2020-2030,($MILLION)
- TABLE 90. LAMEA NEUROMODULATION MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 91. BRAZIL NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 92. BRAZIL NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 93. BRAZIL NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 94. TURKEY NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 95. TURKEY NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 96. TURKEY NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 97. SAUDI ARABIA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 98. SAUDI ARABIA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 99. SAUDI ARABIA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 100. SOUTH AFRICA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 101. SOUTH AFRICA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 102. SOUTH AFRICA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 103. REST OF LAMEA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
- TABLE 104. REST OF LAMEA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 105. REST OF LAMEA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
- TABLE 106.LIVANOVA PLC: COMPANY SNAPSHOT
- TABLE 107.LIVANOVA PLC: OPERATING SEGMENTS
- TABLE 108.LIVANOVA PLC: PRODUCT PORTFOLIO
- TABLE 109.LIVANOVA PLC: NET SALES,
- TABLE 110.LIVANOVA PLC: KEY STRATERGIES
- TABLE 111.NEVRO CORPORATION: COMPANY SNAPSHOT
- TABLE 112.NEVRO CORPORATION: OPERATING SEGMENTS
- TABLE 113.NEVRO CORPORATION: PRODUCT PORTFOLIO
- TABLE 114.NEVRO CORPORATION: NET SALES,
- TABLE 115.NEVRO CORPORATION: KEY STRATERGIES
- TABLE 116.MEDTRONIC: COMPANY SNAPSHOT
- TABLE 117.MEDTRONIC: OPERATING SEGMENTS
- TABLE 118.MEDTRONIC: PRODUCT PORTFOLIO
- TABLE 119.MEDTRONIC: NET SALES,
- TABLE 120.MEDTRONIC: KEY STRATERGIES
- TABLE 121.NEUROSIGMA: COMPANY SNAPSHOT
- TABLE 122.NEUROSIGMA: OPERATING SEGMENTS
- TABLE 123.NEUROSIGMA: PRODUCT PORTFOLIO
- TABLE 124.NEUROSIGMA: NET SALES,
- TABLE 125.NEUROSIGMA: KEY STRATERGIES
- TABLE 126.NEURONETICS: COMPANY SNAPSHOT
- TABLE 127.NEURONETICS: OPERATING SEGMENTS
- TABLE 128.NEURONETICS: PRODUCT PORTFOLIO
- TABLE 129.NEURONETICS: NET SALES,
- TABLE 130.NEURONETICS: KEY STRATERGIES
- TABLE 131.BIOVENTUS INC.: COMPANY SNAPSHOT
- TABLE 132.BIOVENTUS INC.: OPERATING SEGMENTS
- TABLE 133.BIOVENTUS INC.: PRODUCT PORTFOLIO
- TABLE 134.BIOVENTUS INC.: NET SALES,
- TABLE 135.BIOVENTUS INC.: KEY STRATERGIES
- TABLE 136.NEUROPACE INC: COMPANY SNAPSHOT
- TABLE 137.NEUROPACE INC: OPERATING SEGMENTS
- TABLE 138.NEUROPACE INC: PRODUCT PORTFOLIO
- TABLE 139.NEUROPACE INC: NET SALES,
- TABLE 140.NEUROPACE INC: KEY STRATERGIES
- TABLE 141.MICROTRANSPONDER: COMPANY SNAPSHOT
- TABLE 142.MICROTRANSPONDER: OPERATING SEGMENTS
- TABLE 143.MICROTRANSPONDER: PRODUCT PORTFOLIO
- TABLE 144.MICROTRANSPONDER: NET SALES,
- TABLE 145.MICROTRANSPONDER: KEY STRATERGIES
- TABLE 146.MICROTRANSPONDER: COMPANY SNAPSHOT
- TABLE 147.MICROTRANSPONDER: OPERATING SEGMENTS
- TABLE 148.MICROTRANSPONDER: PRODUCT PORTFOLIO
- TABLE 149.MICROTRANSPONDER: NET SALES,
- TABLE 150.MICROTRANSPONDER: KEY STRATERGIES
- TABLE 151.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
- TABLE 152.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
- TABLE 153.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
- TABLE 154.BOSTON SCIENTIFIC CORPORATION: NET SALES,
- TABLE 155.BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
- TABLE 156.ABBOTT: COMPANY SNAPSHOT
- TABLE 157.ABBOTT: OPERATING SEGMENTS
- TABLE 158.ABBOTT: PRODUCT PORTFOLIO
- TABLE 159.ABBOTT: NET SALES,
- TABLE 160.ABBOTT: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.NEUROMODULATION MARKET SEGMENTATION
- FIGURE 2.NEUROMODULATION MARKET,2020-2030
- FIGURE 3.NEUROMODULATION MARKET,2020-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.NEUROMODULATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11.NEUROMODULATION MARKET,BY TECHNOLOGY,2020(%)
- FIGURE 12.COMPARATIVE SHARE ANALYSIS OF INTERNAL NEUROMODULATION NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF EXTERNAL NEUROMODULATION NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 14.NEUROMODULATION MARKET,BY APPLICATION,2020(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CHRONIC PAIN NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF URINARY AND FECAL INCONTINENCE NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MIGRAINE NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF FAILED BACK SYNDROME NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF PARKINSON DISEASE NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF EPILEPSY NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF TREMOR NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DEPRESSION NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHER APPLICATIONS NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 24.NEUROMODULATION MARKET,BY BIOMATERIAL,2020(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF METALLIC BIOMATERIALS NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 26.COMPARATIVE SHARE ANALYSIS OF POLYMERIC BIOMATERIALS NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 27.COMPARATIVE SHARE ANALYSIS OF CERAMIC BIOMATERIALS NEUROMODULATION MARKET,2020-2030(%)
- FIGURE 28.NEUROMODULATION MARKET BY REGION,2020
- FIGURE 29.U.S. NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 30.CANADA NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 31.MEXICO NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 32.GERMANY NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 33.FRANCE NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 34.UNITED KINGDOM NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 35.ITALY NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 36.SPAIN NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 37.REST OF EUROPE NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 38.CHINA NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 39.JAPAN NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 40.INDIA NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 41.AUSTRALIA NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 42.REST OF ASIA-PACIFIC NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 43.BRAZIL NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 44.TURKEY NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 45.SAUDI ARABIA NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 46.SOUTH AFRICA NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 47.REST OF LAMEA NEUROMODULATION MARKET,2020-2030($MILLION)
- FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 52.COMPETITIVE DASHBOARD
- FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 54.LIVANOVA PLC.: NET SALES ,($MILLION)
- FIGURE 55.NEVRO CORPORATION.: NET SALES ,($MILLION)
- FIGURE 56.MEDTRONIC.: NET SALES ,($MILLION)
- FIGURE 57.NEUROSIGMA.: NET SALES ,($MILLION)
- FIGURE 58.NEURONETICS.: NET SALES ,($MILLION)
- FIGURE 59.BIOVENTUS INC..: NET SALES ,($MILLION)
- FIGURE 60.NEUROPACE INC.: NET SALES ,($MILLION)
- FIGURE 61.MICROTRANSPONDER.: NET SALES ,($MILLION)
- FIGURE 62.MICROTRANSPONDER.: NET SALES ,($MILLION)
- FIGURE 63.BOSTON SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
- FIGURE 64.ABBOTT.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook